Skip to content

Author

F. Rumi

We have 2 of 5 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Cost-effectiveness of a single dose of the adjuvanted respiratory syncytial virus preFusion protein 3 vaccine over 5 years and its potential public health impact among older adults in Italy.

Vaccination of OAs and AIR individuals with one dose of aRSVPreF3 has the potential to reduce RSV disease-associated burden and direct costs for the Italian National Healthcare System over a 5-year period.

A. Puggina, Eleftherios Zarkadoulas, F. Rumi et al. · 0 citations
Open access Aug 2026

Cost-Effectiveness Analysis of the mRNA-1345 RSV Vaccine for Older Adults in Italy

Vaccination with mRNA-1345 is a cost-effective strategy for the prevention of RSV in high-risk adults aged 60-74 years and all adults aged [≥]75 years in Italy and has the potential to provide substantial public health benefits.

M. Dronova, C. Moyon, L. Pyrek et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.